imiquimod has been researched along with salubrinal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Chen, Y; He, Y; Li, W; Ma, Y; Shangguan, Y; Zhao, Y | 1 |
2 other study(ies) available for imiquimod and salubrinal
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Salubrinal protects against inflammatory response in macrophage and attenuates psoriasiform skin inflammation by antagonizing NF-κB signaling pathway.
Topics: Animals; Cinnamates; Disease Models, Animal; Imiquimod; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Protective Agents; Psoriasis; RAW 264.7 Cells; Signal Transduction; Skin; Thiourea; Tumor Necrosis Factor-alpha | 2022 |